Aiming to address a significant unmet need for which no other approved treatment option is available for generalized anxiety disorder patients in Japan "The filing of our supplemental New Drug ...
Aiming to address a significant unmet need for which no other approved treatment option is available for generalized anxiety disorder patients in Japan As previously announced, our Phase 3 ...
Such forward-looking statements may include statements regarding the receipt or timing of regulatory approvals; the outcome of clinical trials; the filing of our supplemental New Drug Applications is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback